Your browser doesn't support javascript.
loading
Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.
Sayinzoga, Felix; Umulisa, M Chantal; Sibomana, Hassan; Tenet, Vanessa; Baussano, Iacopo; Clifford, Gary M.
Afiliação
  • Sayinzoga F; Ministry of Health, Rwanda Biomedical Center, Kigali, Rwanda.
  • Umulisa MC; International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France; Université Claude Bernard Lyon 1, Lyon, France.
  • Sibomana H; Ministry of Health, Rwanda Biomedical Center, Kigali, Rwanda.
  • Tenet V; International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France.
  • Baussano I; International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France.
  • Clifford GM; International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. Electronic address: cliffordg@iarc.fr.
Vaccine ; 38(24): 4001-4005, 2020 05 19.
Article em En | MEDLINE | ID: mdl-32336599
BACKGROUND: In 2011, Rwanda became the first African nation to implement a national human papillomavirus (HPV) vaccination program, conceived to protect girls aged <15 years (i.e. born ≥1997). After an initial school-grade-targeted catch-up campaign, there was a transition to routine vaccination of 12 year-olds only. We aimed to produce population-level vaccine coverage estimates. METHODS: The Rwandan Expanded Program on Immunization (EPI) collected data on number of eligible girls and HPV vaccines delivered, stratified by calendar year (2011-2018), girl's age, district and vaccination round. HPV vaccine coverage was estimated by birth cohort (reconstituted using calendar year and age), as a proportion of (1) eligible target, and (2) the 2012 Rwandan census population. RESULTS: 1,156,863 girls received first dose of HPV vaccine between 2011 and 2018, corresponding to 98% of the eligible target. Median vaccination age was 15 years (interquartile range [IQR] 13-16) in 2011-2013 (school grade-targeted catch-up), 13 years (IQR 12-14) in 2014 (transition) and 12 years in 2015-2018 (routine). Population-level coverage versus the census increased from 10 to 40% for girls born in 1993-1995 (median vaccination age = 17 years) to 50-65% for 1996-2000 birth cohorts (14 years), and 80-90% for 2001-2006 birth cohorts (12 years). Coverage trends were similar across provinces and in the capital, Kigali. Second and third round coverage suggested most vaccinated girls completed their recommended dosing regimen (which reduced from 3 to 2 doses in 2015). CONCLUSIONS: Birth cohorts provide a clear picture of population-level HPV vaccine coverage after a pragmatic catch-up campaign, particularly in Rwanda where eligible school grades included wide age ranges. Whilst the catch-up campaign resulted in some coverage gaps in out-of-school teenagers, coverage remains high in cohorts routinely targeted as 12 year-olds.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Programas de Imunização / Infecções por Papillomavirus / Cobertura Vacinal / Vacinas contra Papillomavirus Tipo de estudo: Risk_factors_studies Limite: Adolescent / Child / Female / Humans País/Região como assunto: Africa Idioma: En Revista: Vaccine Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Ruanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Programas de Imunização / Infecções por Papillomavirus / Cobertura Vacinal / Vacinas contra Papillomavirus Tipo de estudo: Risk_factors_studies Limite: Adolescent / Child / Female / Humans País/Região como assunto: Africa Idioma: En Revista: Vaccine Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Ruanda